Search
Tiziana Life Sciences Ltd
TLSAAdd to Watchlist
1.030USD
+0.060+6.19%
Close 07-31 16:00（ET）Quotes delayed by 15 min
124.12MMarket Cap
LossP/E TTM
More Details of Tiziana Life Sciences Ltd Company
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Tiziana Life Sciences Ltd Info
Ticker SymbolTLSA
Company nameTiziana Life Sciences Ltd
IPO dateNov 20, 2018
CEOElrifi (Ivor)
Number of employees8
Security typeOrdinary Share
Fiscal year-endNov 20
Address3rd Floor, 11-12 St. James's Square
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeSW1Y 4LB
Phone442074952379
Websitehttps://www.tizianalifesciences.com/
Ticker SymbolTLSA
IPO dateNov 20, 2018
CEOElrifi (Ivor)
Company Executives of Tiziana Life Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.69M
--
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.69M
--
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
FAQs
Who are the top five shareholders of Tiziana Life Sciences Ltd?
The top five shareholders of Tiziana Life Sciences Ltd are: Mr. Ivor Elrifi
How many institutions hold shares of Tiziana Life Sciences Ltd (TLSA)?
As of 2026Q1, 75 institutions hold shares of Tiziana Life Sciences Ltd, with a combined market value of approximately 3.95M, accounting for 3.10% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2438604.00.